JP Morgan Analyst Maintains Neutral Rating on Clorox with Revised Price Target of $140.00 USD

Analyst Andrea Teixeira from JP Morgan has maintained a "Neutral" rating on Clorox (CLX), with a revised price target of $140.00, down 2.78% from $144.00. The average one-year target price for Clorox is $140.12, implying a 7.12% upside from the current price of $130.81. The estimated GF Value in one year is $144.17, suggesting a 10.21% upside from the current price.

Analyst Andrea Teixeira from JP Morgan has maintained a "Neutral" rating on Clorox (CLX), with a revised price target of $140.00, down 2.78% from the previous target of $144.00. The average one-year target price for CLX is $140.12, implying a 7.12% upside from the current price of $130.81. The estimated GF Value in one year is $144.17, suggesting a 10.21% upside from the current price [1].

The downward revision in the price target reflects a broader trend among analysts, with several other firms also adjusting their targets. Morgan Stanley reduced their target from $165.00 to $150.00, while Citigroup lowered their target from $140.00 to $135.00. Evercore ISI set a target of $140.00 and assigned an "underperform" rating. Barclays decreased their target from $129.00 to $119.00 and set an "underweight" rating. Wells Fargo reduced their target from $142.00 to $135.00 [1].

The consensus rating among analysts remains "Hold," with a consensus price target of $144.83. Despite the downward adjustments, Clorox has shown resilience in its recent earnings, reporting $1.45 EPS for the quarter, although it missed the consensus estimate of $1.57 [1].

Institutional investors have also shown interest in Clorox, with several firms increasing their stakes in the fourth quarter. Redwood Park Advisors LLC, Wood Tarver Financial Group LLC, GKV Capital Management Co. Inc., Aster Capital Management DIFC Ltd, and American National Bank & Trust have all increased their holdings [1].

Clorox, a leading manufacturer of consumer and professional products, operates through four segments: Health and Wellness, Household, Lifestyle, and International. The company's revenue for the quarter was down 8.0% compared to the same period last year, but it maintained a strong net margin of 9.89% and a return on equity of 324.23% [1].

References:
[1] https://www.marketbeat.com/instant-alerts/jpmorgan-chase-co-cuts-clorox-nyseclx-price-target-to-14000-2025-07-25/